Qin H - Search Results

1

Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.

Yan H, Song L, Li Y, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zhang Y, Zeng L. Yan H, et al. Among authors: qin h. Cancer Immunol Immunother. 2024 Mar 7;73(4):74. doi: 10.1007/s00262-024-03660-2. Cancer Immunol Immunother. 2024. PMID: 38451314 Free PMC article.

2

Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study.

Huang Z, Yan H, Zeng L, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Dong X, Yang N, Zhang Y. Huang Z, et al. Among authors: qin h. JCO Precis Oncol. 2023 Mar;7:e2200614. doi: 10.1200/PO.22.00614. JCO Precis Oncol. 2023. PMID: 36952645

3

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.

Song L, Zhou F, Xu T, Zeng L, Xia Q, Wang Z, Deng L, Li Y, Qin H, Yan H, Huang Z, Mi J, Xu Q, Yang N, Zhou C, Zhang Y. Song L, et al. Among authors: qin h. BMC Cancer. 2023 May 16;23(1):443. doi: 10.1186/s12885-023-10952-w. BMC Cancer. 2023. PMID: 37189075 Free PMC article.

4

Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.

Zeng L, Zhou Y, Xu Q, Huang Z, Song L, Wang Z, Deng L, Wu Y, Liang Y, Liu Z, Gao X, Yi X, He Q, Xia X, Yang H, Zhang X, Yan H, Qin H, Lin S, Yang N, Zhang Y. Zeng L, et al. Among authors: qin h. Lung Cancer. 2023 Oct;184:107350. doi: 10.1016/j.lungcan.2023.107350. Epub 2023 Aug 28. Lung Cancer. 2023. PMID: 37659241

5

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.

Zhang Y, Zeng F, Peng S, Chen Y, Jiang W, Wang Z, Deng L, Huang Z, Qin H, Yan H, Zhang X, Zhang L, Yang N, Gong Q, Zeng L, Zhang Y. Zhang Y, et al. Among authors: qin h. Expert Rev Respir Med. 2023 Jul-Dec;17(9):743-751. doi: 10.1080/17476348.2023.2265810. Epub 2023 Oct 27. Expert Rev Respir Med. 2023. PMID: 37776047

6

First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.

Zeng L, Song L, Liu L, Wu F, Xu Q, Yan H, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Xiao J, Liu M, Liu Z, Zhang L, Zhou C, Xiong Y, Wang Y, Zhang Y, Yang N. Zeng L, et al. Among authors: qin h. Med. 2024 May 10;5(5):445-458.e3. doi: 10.1016/j.medj.2024.02.011. Epub 2024 Mar 22. Med. 2024. PMID: 38521070 Clinical Trial.

7

Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.

Huang Z, Zhang Y, Xu Q, Song L, Li Y, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zeng L, Zhang Y. Huang Z, et al. Among authors: qin h. Lung Cancer. 2024 Jun;192:107827. doi: 10.1016/j.lungcan.2024.107827. Epub 2024 May 21. Lung Cancer. 2024. PMID: 38795459

8

Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.

Qin H, Yan H, Chen Y, Xu Q, Huang Z, Jiang W, Wang Z, Deng L, Zhang X, Zhang L, Yang N, Zeng L, Zhang Y. Qin H, et al. BMC Cancer. 2024 Aug 3;24(1):952. doi: 10.1186/s12885-024-12748-y. BMC Cancer. 2024. PMID: 39097705 Free PMC article.

9

Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristics.

Qin H, Huang Z, Yan H, Song L, Zeng L, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Dong X, Yang N, Zhang Y. Qin H, et al. iScience. 2024 Sep 10;27(10):110910. doi: 10.1016/j.isci.2024.110910. eCollection 2024 Oct 18. iScience. 2024. PMID: 39351193 Free PMC article.

10

Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells.

Li N, Qin H, Zhu F, Ding H, Chen Y, Lin Y, Deng R, Ma T, Lv Y, Xiong C, Li R, Wei Y, Shi J, Chen H, Zhao Y, Zhou G, Guo H, Lv M, Lin Y, Han B, Nie G, Zhao R. Li N, et al. Among authors: qin h. Nat Biomed Eng. 2024 Dec 27. doi: 10.1038/s41551-024-01309-0. Online ahead of print. Nat Biomed Eng. 2024. PMID: 39730914

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,727 results

Search Page

Filters